FDA Brief

Warning letters Biologics

FDA warning letter to

Davati Medical Supply LLC

High riskIssued Jun 25, 2021Posted Jul 6, 2021Center for Biologics Evaluation and Research

FDA warned Davati Medical Supply for selling unapproved, unlicensed FLUZALP Quadrivalent influenza vaccine online in the U.S.

What happened

FDA reviewed www.davatimedical.com on June 22, 2021, and found the site directed consumers to contact Davati to buy FLUZALP Quadrivalent influenza vaccine, represented as made by Anzalp Pharmasolutions. FDA said the product is intended to prevent or treat influenza in people but is not approved or licensed for U.S. sale; the website also claimed FDA tests each batch before release.

What FDA found

  1. Davati offered an influenza vaccine for sale in the U.S. without FDA approval as a new drug.

    section 505 of the FD&C Act, 21 U.S.C. § 355
  2. The product was misbranded because it was offered with claims that misrepresented it as safe and effective for influenza prevention.

    section 502 of the FD&C Act, 21 U.S.C. § 352
  3. The product was an unlicensed biological product because no biologics license was in effect.

    section 351 of the PHS Act, 42 U.S.C. § 262
  4. There was no approved biologics license application or investigational new drug application in effect for the product.

    21 U.S.C. § 355(i); 42 U.S.C. § 262(a)(3); 21 CFR Part 312
  5. Introducing or delivering the product into interstate commerce was prohibited.

    sections 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331(a) and (d)

What FDA wants

FDA tells Davati to stop selling the product immediately and, within 48 hours, email CBER with the steps taken, an explanation of how recurrence will be prevented, and supporting documents. If it cannot fully correct the matter in 48 hours, it must state why and give a timeline.

Who should pay attention

  • clinics, pharmacies, and online sellers considering imported flu vaccines
  • U.S. distributors and importers of biologics
  • companies sourcing vaccines from Anzalp Pharmasolutions or Davati

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk